| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $16.7M | — | +233.6% |
| SG&A Expense | $1.3M | — | +1.6% |
| Operating Income | -$18.0M | — | -186.7% |
| Income Tax | $0 | — | — |
| Net Income | -$17.6M | — | -218.0% |
| EPS (Basic) | -$0.63 | — | -96.9% |
| EPS (Diluted) | -$0.63 | — | -96.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $14.2M | -27.2% | -36.1% |
| Total Assets | $16.2M | -22.9% | -39.2% |
| Current Liabilities | $12.8M | +251.8% | +410.7% |
| Total Liabilities | $13.1M | +210.1% | +388.9% |
| Stockholders' Equity | $3.1M | -81.4% | -87.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.0M | — | -11.3% |
| Financing Cash Flow | $3.7M | — | -81.3% |